Drugs / FXIII Concentrate (Human)
FXIII Concentrate (Human)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00883090 | May 2009 → Apr 2010 | factor XIII deficiency | CSL Behring | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00885742 | Aug 2009 → Apr 2011 | factor XIII deficiency | CSL Behring | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FXIII Concentrate (Human) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00885742 ↗ |
| Action | Restore | “Factor XIII Concentrate (Human) works by assisting your blood in the usual clotting process, thereby preventing bleeding.” NCT00883090 ↗ |
| Modality | Protein / enzyme biologic | “Human Plasma-Derived Factor XIII Concentrate” NCT00883090 ↗ |
| Route | Intravenous | “administered as a bolus intravenous (IV) injection” NCT00883090 ↗ |